A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
Tru Niagen® was recognized for its industry-leading research, increased presence on cross-border e-commerce channels, and high engagement on several social media platforms in Mainland China LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company...
Tru Niagen® to debut at NHNE via a celebration press conference following the expo's opening ceremony LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) today announced that Sinopharm Xingsha will debut Tru Niagen® at the major mainland China trade show, China...
Brazil is the first Latin American country to now welcome Tru Niagen®, with a strategy focused on reaching both consumers and Health Care Practitioners (HCPs) LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) today announced a partnership with MyPharma2Go to conduct...
The "807" patent held under exclusive license covers compositions comprising NAD+ precursor nicotinamide riboside LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) ("the Company") a global bioscience company dedicated to healthy aging, announced the U.S. Patent &...
Total net sales of $16.7 million for the three months ended June 30, 2022 with $14.5 million from Tru Niagen® and gross margin of 60.0% for the quarter LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the second quarter of 2022....
LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wed. August 10, 2022 at 4:30 p.m. ET to discuss its financial results for the second quarter, which ended June 30, 2022. The financial results will be reported in a press...
Webinar Featuring Dr. Charles Brenner LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) today announced that it will host a key opinion leader (KOL) webinar on the transforming benefits of nicotinamide riboside (NR) on Wednesday, July 20, 2022 at 11:00 am Eastern Time. The...
As a pioneer of nicotinamide adenine dinucleotide (NAD+) and healthy aging research, ChromaDex aims to raise awareness amongst industry leaders LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) today announced that members of its team, a Scientific Advisory Board member and...
Under the distribution agreement, all cross-border operations in the region will be transitioned to Sinopharm, with Sinopharm investments to amplify Tru Niagen® brand awareness, as a first step in ChromaDex's recently announced China Joint Venture agreement LOS...
LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presenting at Oppenheimer's 22nd Annual Consumer Growth and E-Commerce Conference. The ChromaDex management team...